1519 Topical type VII collagen increased elastic fiber formation, accelerated wound closure and reduced scarring of diabetic pigskin wounds.

Impaired wound healing and consequent chronic wounds, such as diabetic foot ulcers, are a major medical complication of diabetes, growing problem with significant medical, economic social implications worldwide. Currently, there is paucity effective therapy for skin wounds. We have shown previously in several murine models that recombinant human type VII collagen (rhC7) dramatically accelerates closure inhibits scarring. Here, we evaluated the effect topical rhC7 on full-thickness wounds made pigs streptozocin-induced diabetes. Pigskin most similar to all known species. found pigskin treated topically exhibited marked acceleration due increased re-epithelialization when compared vehicle alone (VE), platelet-derived growth factor (the only FDA-approved agent) or Dermacol. assessed healed elements scarring by immunohistochemistry histology. In decreased fibrogenic TGF-β1 anti-fibrogenic TGF-β3. Consistent less scar formation, reduced deposition, α-smooth muscle actin positive myofibroblasts, connective tissue factor, tenascin-C, fibronectin, periostin also inflammation angiogenesis. Compared VE, rhC7-treated had expression VIII markers including Ly6G, CD11b, CD45, F4/80, CD4, IL17, B220, well IL-6, pro-inflammatory cytokine stimulate fibrosis. Most interestingly, robust, elastic fiber formation VE-treated conclude increases generation, closure, reduces may be novel therapeutic agent treating